Form 4: Exelixis CSO Dana Aftab Reports Stock Sale
SEC Form 4
Dana Aftab, CSO/EVP of Discovery & Translational Research at Exelixis, sold 26,987 shares of common stock at $36.75 on February 24, 2025.
Summary
- On February 24, 2025, Dana Aftab, the CSO/EVP of Discovery & Translational Research at Exelixis, sold 26,987 shares of Exelixis common stock at a price of $36.75 per share.
- Following the transaction, Aftab directly owns 511,908 shares of Exelixis common stock, which includes 259,043 shares issuable upon vesting of restricted stock units (RSUs).
- Aftab also indirectly owns 5,835 shares of common stock through the Exelixis, Inc. 401(k) Plan.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard insider transaction report. The sale itself doesn't necessarily indicate a positive or negative outlook.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into the trading activities of company executives.
Stakeholder Impact
- The stock sale by a company officer could be perceived differently by stakeholders; some may see it as a lack of confidence, while others may view it as a personal financial decision.
Key Dates
| Date | Description |
|---|---|
| 02/24/2025 | Date of stock sale transaction and 401(k) plan statement. |
| 02/26/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.